Global Smart Insulin Pens and Pump Market Size By Type (Smart Insulin Pens, Smart Insulin Pump), By Application (Hospitals and Clinics, Homecare), By Region, And Segment Forecasts, 2023 to 2032

The Global Smart Insulin Pens and Pump Market was valued at USD 5.3 billion in 2023 and is projected to reach USD 12.9 billion by 2031, growing at a CAGR of 11.9% during the forecast period from 2023 to 2031. This rapid growth is driven by the rising global prevalence of diabetes, the increasing demand for technologically advanced insulin delivery devices, and growing patient preference for convenient and accurate insulin management solutions. Smart insulin pens and pumps are transforming diabetes care by offering enhanced dosing accuracy, data integration with mobile health platforms, and improved adherence to treatment regimens, thereby improving patient outcomes and quality of life.

Drivers:

Rising Global Diabetes Prevalence

The increasing incidence of both Type 1 and Type 2 diabetes worldwide is a major growth driver. According to international health organizations, millions of people are diagnosed with diabetes annually, creating a sustained demand for efficient insulin delivery devices.

Technological Advancements in Insulin Delivery Devices

The development of Bluetooth-enabled smart pens and sensor-integrated insulin pumps has revolutionized diabetes management. These innovations facilitate real-time glucose monitoring, automatic dose tracking, and seamless data sharing with healthcare providers, fostering widespread adoption.

Growing Demand for Personalized and Remote Healthcare

With the expansion of digital health, patients and clinicians are increasingly adopting devices that offer remote monitoring and personalized treatment. Smart insulin pens and pumps align with this trend, driving their global uptake.

Restraints:

High Cost of Smart Devices

Despite technological advantages, the high cost of smart insulin pens and pumps remains a barrier to widespread adoption, particularly in low- and middle-income countries where access to advanced diabetes care is limited.

Data Privacy and Security Concerns

The digital nature of smart insulin delivery systems raises concerns regarding data privacy, cybersecurity, and regulatory compliance, especially as these devices collect sensitive health information.

Opportunity:

Expansion in Emerging Markets

Emerging economies in Asia-Pacific and Latin America are experiencing rising diabetes rates and increasing healthcare investment, offering significant growth potential for smart insulin device manufacturers.

Integration with Artificial Intelligence and IoT

The integration of smart insulin pens and pumps with AI-driven platforms and Internet of Things (IoT) ecosystems presents new opportunities for predictive analytics, personalized treatment plans, and enhanced disease management.

Market by System Type Insights:

By system type, Smart Insulin Pumps dominated the market in 2023, accounting for the largest revenue share. Their continuous and programmable insulin delivery, coupled with real-time glucose monitoring features, make them highly preferred by patients with Type 1 diabetes. Meanwhile, Smart Insulin Pens are gaining traction for their portability, ease of use, and appeal among Type 2 diabetes patients. This segment is expected to grow rapidly during the forecast period due to increasing product launches and affordability.

Market by End-use Insights:

Based on end-use, the Hospitals & Clinics segment was the leading revenue contributor in 2023, driven by the high volume of patients requiring supervised insulin therapy. However, the Home Care Settings segment is anticipated to exhibit the highest growth rate through 2031. As patients seek autonomy and convenience in managing chronic conditions, home-based insulin delivery devices are witnessing growing acceptance.

Market by Regional Insights:

North America held the largest market share in 2023, attributed to its high diabetes prevalence, advanced healthcare infrastructure, and strong presence of key players. However, Asia-Pacific is expected to emerge as the fastest-growing region, fueled by increasing disease awareness, expanding healthcare access, and supportive government initiatives for diabetes management in countries like India and China.

Competitive Scenario:

Prominent players in the Global Smart Insulin Pens and Pump Market include Medtronic plc, Novo Nordisk A/S, Insulet Corporation, Tandem Diabetes Care, Inc., Eli Lilly and Company, Ypsomed AG, Bigfoot Biomedical, Emperra GmbH, and Companion Medical. These companies are investing in R&D, forming strategic collaborations, and launching innovative solutions to capture market share.

In 2024, Medtronic introduced its MiniMed™ 780G insulin pump system with automated insulin delivery features in multiple global markets.

Novo Nordisk launched the next-gen NovoPen® 7 with enhanced connectivity features in 2023.

Insulet Corporation expanded its Omnipod DASH® system into Asia-Pacific through new regional partnerships in 2025.

Scope of Work – Global Smart Insulin Pens and Pump Market

Report Metric Details

Market Size (2023) USD 5.3 billion

Projected Market Size (2031) USD 12.9 billion

CAGR (2023–2031) 11.9%

Market Segments By System Type (Smart Insulin Pens, Smart Insulin Pumps), By End-use (Hospitals & Clinics, Home Care Settings), By Region

Growth Drivers Rising global diabetes cases, technological innovations, increasing demand for personalized healthcare

Opportunities Expansion in emerging markets, integration with AI and IoT

Key Market Developments:

2023: Novo Nordisk introduced the upgraded NovoPen® 7 with improved digital tracking and mobile app synchronization.

2024: Medtronic received regulatory approval for its MiniMed™ 780G in the EU, enabling broader market expansion.

2025: Tandem Diabetes Care partnered with a leading AI platform to develop a predictive insulin delivery feature